This New Drug Nearly Doubled Survival Time For Pancreatic Cancer Patients

Reported by MindBodyGreen.

For nearly four decades, oncologists watched patients die from cancers driven by a mutation they could identify but not touch. The KRAS gene — responsible for fueling some of the deadliest tumors in pancreatic, lung, and colorectal cancers — earned the grim nickname "undruggable" because its protein surface offered no foothold for a blocking molecule. That word may finally be obsolete.

A drug called daraxonrasib produced results so striking at the 2026 American Society of Clinical Oncology annual meeting that the audience gave them a standing ovation, according to MindBodyGreen. The phase 3 trial enrolled 500 patients with metastatic pancreatic cancer whose disease had stopped responding to first-line chemotherapy — one of the hardest populations in oncology to treat, where standard second-line options have historically offered median survival of just 4.8 to 5.9 months. Patients on daraxonrasib lived an average of 13.2 months, compared to 6.7 months on standard chemotherapy — a 60% reduction in the risk of death. Tumor shrinkage was nearly three times higher: 33% versus 12%. And only 1.2% of daraxonrasib patients stopped treatment due to side effects, compared to 11.2% on chemo. That tolerability gap matters enormously for people already carrying a brutal diagnosis.

The mechanism driving these numbers is what makes researchers genuinely excited. Rather than attacking the KRAS protein directly — which failed for decades because the surface was too smooth — daraxonrasib uses a "molecular glue" approach: it binds a helper protein onto the mutant KRAS and locks it in an off position, cutting off the growth signals that feed the cancer. It works across multiple KRAS mutation types, not just one, which is where the story gets significantly bigger.

Why This Goes Far Beyond Pancreatic Cancer

KRAS mutations are among the most common cancer drivers in humans. The specific variant daraxonrasib targets accounts for roughly 40% of pancreatic cancers, 25% of lung cancers, and 40% of colorectal cancers. The molecular glue mechanism that worked here is already being tested in those tumor types, following a pattern scientists saw with BRCA mutations — a breakthrough in one cancer that rippled across many others. Daraxonrasib is not yet commercially available, but phase 3 data of this caliber typically precedes an FDA submission within months. In the meantime, if you or someone you know is navigating any KRAS-associated diagnosis, asking your oncologist about molecular tumor testing and current clinical trial access is a concrete, actionable first step.

After 40 years of watching a known killer operate without consequence, science finally has a mechanism that works — and the survival numbers to prove it.

Read the original at MindBodyGreen.